MEI Pharma (Nasdaq:MEIP) - Aandelenkoers, Nieuws & Analyse

MEIP Overzicht aandelen

MEI Pharma, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van verschillende therapieën voor de behandeling van kanker.

Over het bedrijf

MEIP fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	2/6

Beloningen

De koers-winstverhouding ( 1.2 x) ligt onder de US markt ( 18 x)

Dit jaar winstgevend geworden

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 35.5% per jaar dalen.

Heeft geen betekenisvolle marktkapitalisatie ( $20M )

Grote eenmalige posten die de financiële resultaten beïnvloeden

MEI Pharma, Inc. Concurrenten

PharmaCyte Biotech

NasdaqCM:PMCB

US$14.1m

CytomX Therapeutics

NasdaqGS:CTMX

US$82.0m

Eagle Pharmaceuticals

OTCPK:EGRX

US$7.1m

Spero Therapeutics

NasdaqGS:SPRO

US$63.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor MEI Pharma
Historische aandelenkoersen
Huidige aandelenkoers	US$3.07
52 Week Hoogtepunt	US$7.87
52 Week Laag	US$2.61
Bèta	0.73
11 maand verandering	9.25%
3 maanden verandering	-11.27%
1 Jaar Verandering	-56.88%
33 jaar verandering	-95.03%
5 jaar verandering	-91.61%
Verandering sinds IPO	-99.97%

Recent nieuws en updates

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 17

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Dec 30

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Mar 26

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Feb 12

MEI Pharma: Another PI3K Delta Progressing To The FDA

Feb 01

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Dec 02

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 11

Rendement voor aandeelhouders

	MEIP	US Biotechs	US Markt
7D	12.5%	-0.4%	-1.2%
1Y	-56.9%	20.1%	30.6%

Rendement versus industrie: MEIP presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 20.1 % opleverde.

Rendement versus markt: MEIP presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.

Prijsvolatiliteit

Is MEIP's price volatile compared to industry and market?
MEIP volatility
MEIP Average Weekly Movement	6.2%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: MEIP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van MEIP is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	28	Jay File	meipharma.com

MEI Pharma, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van verschillende therapieën voor de behandeling van kanker. Het ontwikkelt ME-344, een intraveneuze kleine molecule remmer mitochondriale oxidatieve fosforylering voor de behandeling van humane epidermale groeifactor receptor 2 negatieve borstkanker, colorectale kanker en solide tumoren. Het bedrijf was voorheen bekend als Marshall Edwards, Inc. en veranderde zijn naam in MEI Pharma, Inc. in juli 2012.

MEI Pharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van MEI Pharma zich tot de beurswaarde?
MEIP fundamentele statistieken
Marktkapitalisatie	US$20.45m
Inkomsten(TTM)	US$17.78m
Inkomsten(TTM)	US$65.30m

1.2x

Koers/Winstverhouding

0.3x

P/S-verhouding

Is MEIP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MEIP resultatenrekening (TTM)
Inkomsten	US$65.30m
Kosten van inkomsten	US$15.97m
Brutowinst	US$49.33m
Overige uitgaven	US$31.55m
Inkomsten	US$17.78m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	2.67
Brutomarge	75.54%
Nettowinstmarge	27.23%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MEIP op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

57.0%

Huidig dividendrendement

n/a

Uitbetalingsratio

MEIP Overzicht aandelen

Beloningen

Risicoanalyse

MEI Pharma, Inc. Concurrenten

NasdaqCM:PMCB

US$14.1m

NasdaqGS:CTMX

US$82.0m

OTCPK:EGRX

US$7.1m

NasdaqGS:SPRO

US$63.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Consensus revenue estimates increase by 26%

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

Price target decreased to US$4.81

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma